Related Experiment Video
Updated: Jun 15, 2026

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
Published on: February 23, 2024
Effects of iron deprivation on multidrug resistance of leukemic K562 cells
Dingzhu Fang1, Yixiao Bao, Xiaobin Li
1Department of Pediatrics, Affiliated XinHua Hospital, Jiaotong University, Shanghai, China.
Background And Aim:
Multidrug resistance (MDR) compromises the efficacy of chemotherapy. Many approaches have been used to reduce MDR; however, the results are poor. It has been reported that iron deprivation downregulates MDR genes. To investigate the relationship of iron with MDR and early growth response gene-1 (EGR1), we investigated the effect of iron deprivation on expression and/or function of multidrug resistance-1 (MDR1), early growth response gene-1 (EGR1), ferritin heavy chain gene (H-Fn) and MDR1-encoded P-glycoprotein (P-gp) in the K562 leukemic cell line.
Methods:
The cells were stimulated with 12-O-tetradecanoylphorbol-13-acetate (TPA) and incubated with either FeCl(3) or the iron-chelating drug DFO. The mRNA levels of MDR1, EGR1 and H-Fn were detected by RT-PCR. The protein expression and function of P-gp were measured by immunohistochemical staining and flow cytometry, respectively.
Results:
DFO significantly reduced the intracellular iron level, and led to approximately 70% reduction of MDR1 mRNA, approximately 50% of reduction of H-Fn mRNA and approximately 30% reduction of P-gp protein in TPA-differentiated K562 cells. The P-gp pump function, measured by daunorubicin exclusion, was also reduced by DFO treatment.
Conclusions:
These results suggest a close relationship between iron deprivation and reduced MDR1/P-gp expression and function. DFO may be used together with chemotherapeutic drugs to achieve better clinical efficacy.
Insights
Iron deprivation significantly reduces multidrug resistance (MDR) by downregulating MDR1 gene and P-glycoprotein (P-gp) expression and function in K562 leukemia cells. This suggests DFO could enhance chemotherapy efficacy.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Multidrug resistance (MDR) significantly hinders chemotherapy effectiveness.
- Existing strategies to overcome MDR have yielded limited success.
- Iron deprivation has been implicated in downregulating MDR genes.
Purpose of the Study:
- To investigate the impact of iron deprivation on MDR and related genes, specifically MDR1, EGR1, H-Fn, and P-gp.
- To explore the relationship between iron levels and MDR in the K562 leukemic cell line.
Main Methods:
- K562 cells were treated with TPA and either FeCl3 or the iron chelator DFO.
- mRNA levels of MDR1, EGR1, and H-Fn were quantified using RT-PCR.
- P-gp protein expression and function were assessed via immunohistochemistry and daunorubicin exclusion assays, respectively.
Main Results:
- DFO treatment markedly decreased intracellular iron levels.
- Significant reductions were observed in MDR1 mRNA (~70%), H-Fn mRNA (~50%), and P-gp protein (~30%).
- DFO also diminished P-gp pump function, as indicated by increased daunorubicin retention.
Conclusions:
- A strong correlation exists between iron deprivation and reduced MDR1/P-gp expression and function.
- Deferoxamine (DFO) shows potential as an adjunct therapy to improve clinical outcomes in chemotherapy.
Related Concept Videos
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Antiprotozoal Agents

